Answers are grounded in this paper and cite their sources.
-targeted ASO provides long-lasting suppression, reverses GFAP pathology, and, depending on age of treatment, prevents or mitigates white matter deficits and motor impairment. In this report, we characterize an improved animal model of AxD with myelin pathology and motor impairment, recapitulating prominent features of the human disease, and use this model to show that ASO therapy has the potential to not only prevent but also reverse many aspects of disease.
No takes yet. Share an insight, caveat, or question.
Hagemann et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: